10-Q: Enanta Pharmaceuticals Reports Q2 2025 Results: Revenue Declines Amidst Advancing Clinical Programs

Enanta Pharmaceuticals reports a decrease in revenue for Q2 2025 due to lower HCV sales, while highlighting progress in RSV and immunology programs.

Summary

• Enanta Pharmaceuticals reported a net loss of $22.644 million, or $1.06 per share, for the three months ended March 31, 2025, compared to a net loss of $31.157 million, or $1.47 per share, for the same period in 2024.
• Revenue decreased to $14.926 million from $17.054 million year-over-year, primarily due to lower HCV sales by AbbVie.
• Research and development expenses decreased to $28.065 million from $35.585 million year-over-year, mainly due to the timing of clinical trials in the RSV program.
• General and administrative expenses decreased to $11.388 million from $14.235 million year-over-year, primarily due to lower legal expenses related to the patent infringement suit against Pfizer.
• The company's cash, cash equivalents, and short-term marketable securities totaled $193.4 million as of March 31, 2025.
• Enanta expects its current financial resources, including a $33.8 million federal tax refund received in April 2025, to fund operations into fiscal year 2028.
• The company is advancing clinical programs in RSV, including zelicapavir and EDP-323, and preclinical programs in immunology targeting KIT and STAT6.
• Enanta has a royalty sale agreement with OMERS, where 54.5% of future MAVYRET/MAVIRET royalties are paid to OMERS until a capped amount is reached.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company reported a decrease in revenue and a net loss, it also highlighted positive clinical trial results and sufficient cash to fund operations into fiscal 2028. The company's reliance on AbbVie's HCV sales and the unsuccessful patent infringement suit against Pfizer are negative factors.

Positives

• Net loss decreased from $31.157 million to $22.644 million year-over-year for the three months ended March 31, 2025.
• Research and development expenses decreased, indicating improved cost management.
• The company has sufficient cash to fund operations into fiscal year 2028.
• Positive topline results from Phase 2 studies of zelicapavir in pediatric patients and EDP-323 in healthy adults infected with RSV were announced.
• The company is advancing preclinical programs in immunology, including KIT and STAT6 inhibitors.
• A $33.8 million federal tax refund was received in April 2025, boosting the company's financial position.

Negatives

• Revenue decreased due to lower HCV sales by AbbVie.
• The company continues to report a net loss.
• The company is dependent on AbbVie's HCV sales for royalty revenue.
• The company's patent infringement suit against Pfizer was unsuccessful at the District Court level, and the company has filed a notice of appeal.

Risks

• The company's future capital requirements are difficult to forecast and will depend on many factors.
• The successful development of the company's product candidates is highly uncertain and may not result in approved products.
• The company is subject to risks common to companies in the biotechnology industry, including uncertainties of research and development, competition, and dependence on collaborative arrangements.
• The company's royalty revenue is dependent on AbbVie's HCV market share and pricing of MAVYRET/MAVIRET.
• The company's appeal of the District Court's decision in the patent infringement suit against Pfizer is uncertain.

Future Outlook

Enanta expects its existing cash, cash equivalents, short-term marketable securities, as well as the cash flows from its retained portion of future HCV royalties and its $33.8 million federal tax refund received in April 2025, will enable it to fund its operating expenses and capital expenditure requirements into fiscal 2028.

Management Comments

• We will evaluate potential partnership opportunities to advance our RSV programs to the next stage of clinical development.
• We will continue to focus on potential collaborations to progress EDP-235, as we will not advance this candidate into Phase 3 studies on our own.
• We plan to expand our presence in immunology with the introduction of a third program in 2025.

Industry Context

Enanta is operating in the competitive biotechnology industry, focusing on virology and immunology. The company's RSV program is targeting a significant unmet need, with RSV being a leading cause of hospitalization in young children and older adults. The immunology programs are addressing inflammatory diseases with high prevalence, such as chronic spontaneous urticaria and atopic dermatitis. The company's success depends on the clinical and regulatory success of its product candidates, as well as its ability to secure collaborations and partnerships.

Comparison to Industry Standards

• Enanta's reliance on royalty revenue from AbbVie's MAVYRET/MAVIRET is similar to other biotech companies that have out-licensed their discoveries to larger pharmaceutical firms.
• The company's focus on RSV is in line with the industry's increasing attention to respiratory viruses, with companies like GSK, Pfizer, and Moderna also developing RSV vaccines and therapeutics.
• Enanta's immunology programs targeting KIT and STAT6 are addressing validated targets in inflammatory diseases, similar to approaches taken by companies like Incyte and Eli Lilly.
• The company's cash runway into fiscal 2028 is comparable to other biotech companies of similar size and stage of development.

Legal Proceedings

• In June 2022, the Company announced that it filed suit in the United States District Court for the District of Massachusetts on June 21, 2022, against Pfizer, Inc. seeking damages for infringement of U.S. Patent No. 11,358,953 (the 953 Patent) in the manufacture, use and sale of Pfizers COVID-19 antiviral, Paxlovid (nirmatrelvir tablets; ritonavir tablets).
• On December 23, 2024, the District Court issued a summary judgment decision ruling that the asserted claims of the 953 Patent were invalid.
• On February 3, 2025, the Company filed a notice of appeal with the United States Court of Appeals for the Federal Circuit.

Related Party Transactions

• In April 2023, the Company entered into a royalty sale agreement with an affiliate of OMERS, pursuant to which the Company was paid a $ 200,000 cash purchase price in exchange for 54.5 % of future quarterly royalty payments on net sales of MAVYRET/MAVIRET, after June 30, 2023, through June 30, 2032, subject to a cap on aggregate payments equal to 1.42 times the purchase price.

Stakeholder Impact

• Shareholders: The decrease in revenue and continued net loss may negatively impact shareholder value.
• Employees: The company's ability to fund operations into fiscal 2028 provides job security for employees.
• Customers: The company's focus on developing new therapies for RSV and inflammatory diseases may benefit patients.
• Suppliers: The company's research and development activities support contracts with suppliers of research materials and services.
• Creditors: The company's strong cash position reduces the risk of default on its obligations.

Next Steps

• Continue Phase 2b study in high-risk adults with RSV, with topline data expected in late third quarter of 2025.
• Evaluate potential partnership opportunities to advance RSV programs.
• Focus on potential collaborations to progress EDP-235.
• Conduct scale-up activities and IND-enabling studies for EPS-1421.
• Continue preclinical studies for STAT6 inhibitor program, with the goal of selecting a lead development candidate in the second half of 2025.
• Pursue appeal of the District Court's decision in the patent infringement suit against Pfizer.

Key Dates

Keywords

RSV, Zelicapavir, EDP-323, MAVYRET, HCV, Immunology, KIT Inhibitors, STAT6 Inhibitors, Clinical Trials, Biotechnology, Pharmaceuticals, Revenue, Net Loss, Research and Development